Quantcast

Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.

Research paper by Kameshwar K Prasad, Reed R Siemieniuk, Qiukui Q Hao, Gordon G Guyatt, Martin M O'Donnell, Lyubov L Lytvyn, Anja Fog AF Heen, Thomas T Agoritsas, Per Olav PO Vandvik, Sankar Prasad SP Gorthi, Loraine L Fisch, Mirza M Jusufovic, Jennifer J Muller, Brenda B Booth, Eleanor E Horton, et al.

Indexed on: 20 Dec '18Published on: 20 Dec '18Published in: BMJ (Clinical research ed.)



Abstract

WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

More like this: